1. Home
  2. PDX vs TBPH Comparison

PDX vs TBPH Comparison

Compare PDX & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PIMCO Dynamic Income Strategy Fund of Beneficial Interest

PDX

PIMCO Dynamic Income Strategy Fund of Beneficial Interest

HOLD

Current Price

$21.66

Market Cap

920.1M

Sector

Finance

ML Signal

HOLD

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$16.52

Market Cap

824.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PDX
TBPH
Founded
2019
2013
Country
NY
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
920.1M
824.9M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
PDX
TBPH
Price
$21.66
$16.52
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
$18.40
AVG Volume (30 Days)
93.3K
292.0K
Earning Date
01-01-0001
05-04-2026
Dividend Yield
4.95%
N/A
EPS Growth
N/A
279.13
EPS
N/A
N/A
Revenue
N/A
$15,386,000.00
Revenue This Year
N/A
$8.46
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$18.47
$9.10
52 Week High
$25.25
$21.03

Technical Indicators

Market Signals
Indicator
PDX
TBPH
Relative Strength Index (RSI) 61.95 50.10
Support Level $21.50 $16.14
Resistance Level $22.20 $17.21
Average True Range (ATR) 0.32 0.38
MACD 0.05 -0.08
Stochastic Oscillator 70.67 43.53

Price Performance

Historical Comparison
PDX
TBPH

About PDX PIMCO Dynamic Income Strategy Fund of Beneficial Interest

PIMCO Dynamic Income Strategy Fund is a non-diversified, limited-term, closed-end management investment company. It seeks current income as a primary objective and capital appreciation as a secondary objective. The fund makes investments using a dynamic asset allocation plan among multiple sectors in the public and private credit markets globally, including corporate debt, mortgage-related and other asset-backed instruments, government and sovereign debt, taxable municipal bonds, and other fixed, variable, and floating-rate income-producing securities of U.S. and foreign issuers, including emerging market issuers and real estate-related investments.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.

Share on Social Networks: